Overview
Protein C is an endogenously occurring plasma protein that plays a key role within the coagulation cascade. Protein C is a zymogen, or enzyme precursor, of a vitamin K-dependent anticoagulant glycoprotein (serine protease) that is synthesized in the liver. It is converted by the thrombin/thrombomodulin-complex on the endothelial cell surface to Activated Protein C (APC). Once in its activated form, APC functions as a serine protease with potent anticoagulant effects, especially in the presence of its cofactor protein S. APC exerts its effect by inactivating essential components of the coagulation cascade (specifically factors V and VIII), which leads to a decrease in thrombin formation, and therefore a reduction in clot formation. The Protein C pathway provides a natural mechanism for control of the coagulation system and prevention of excessive procoagulant responses to activating stimuli. A lack of protein C in the body would lead to unchecked coagulation activation, resulting in thrombin generation and intravascular clot formation. Protein C is available in concentrated form as the product Ceprotin, which is indicated for use in pediatric and adult patients with severe congenital protein C deficiency for the prevention and treatment of venous thrombosis and purpura fulminans.
Indication
Protein C concentrate is indicated for pediatric and adult patients with severe congenital protein C deficiency for the prevention and treatment of venous thrombosis and purpura fulminans. It is also found as a component of some prothrombin complex concentrate (i.e. Factor IX Complex (Human)) formulations, such as Kcentra.
Associated Conditions
- Purpura Fulminans
- Venous Thrombosis (Disorder)
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
---|---|---|---|---|---|
2021/08/02 | Phase 1 | Completed | |||
2012/10/12 | Phase 3 | Terminated | |||
2011/08/08 | Phase 2 | Completed | University of Roma La Sapienza |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
---|---|---|---|---|---|
No FDA approvals found for this drug. |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
---|---|---|---|
Authorised | 7/16/2001 |
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
OCTAPLEX POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 500 IU | SIN14933P | INJECTION, POWDER, FOR SOLUTION | 260 - 620 IU/vial | 1/28/2016 |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
---|---|---|---|---|---|
No NMPA approvals found for this drug. |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
---|---|---|---|---|---|
No PPB approvals found for this drug. |
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
---|---|---|---|---|---|
CEPROTIN protein c 1000IU powder for injection vial with diluent vial | 104538 | Medicine | A | 6/30/2005 | |
BERIPLEX AU human prothrombin complex 250 IU powder for injection vial | 328514 | Medicine | A | 7/7/2020 | |
CEPROTIN protein c 500IU powder for injection vial with diluent vial | 104537 | Medicine | A | 6/30/2005 | |
BERIPLEX P/N human prothrombin complex 250 IU powder for injection vial | 156330 | Medicine | A | 2/5/2010 | |
BERIPLEX AU human prothrombin complex 1000 IU powder for injection vial | 328516 | Medicine | A | 7/7/2020 | |
BERIPLEX AU human prothrombin complex 500 IU powder for injection vial | 328515 | Medicine | A | 7/7/2020 | |
BERIPLEX P/N human prothrombin complex 500 IU powder for injection vial | 156459 | Medicine | A | 2/5/2010 | |
PRONATIV human prothrombin complex powder for injection vial and solution for injection vial | 129151 | Octapharma Australia Pty Ltd | Medicine | A | 10/12/2007 |
BERIPLEX P/N human prothrombin complex 1000 IU powder for injection vial | 228338 | Medicine | A | 8/5/2015 |
Help Us Improve
Your feedback helps us provide better drug information and insights.